Zoetis Inc. (NYSE:ZTS) declared a quarterly dividend on Friday, October 7th. Stockholders of record on Thursday, November 3rd will be paid a dividend of 0.095 per share on Thursday, December 1st. This represents a $0.38 dividend on an annualized basis and a dividend yield of 0.73%. The ex-dividend date is Tuesday, November 1st.
Zoetis (NYSE:ZTS) opened at 51.85 on Monday. Zoetis has a 52 week low of $38.26 and a 52 week high of $52.64. The stock has a 50 day moving average price of $51.24 and a 200-day moving average price of $48.75. The stock has a market cap of $25.67 billion, a P/E ratio of 40.38 and a beta of 1.01.
Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Wednesday, August 3rd. The company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.44 by $0.05. The firm earned $1.20 billion during the quarter, compared to the consensus estimate of $1.17 billion. Zoetis had a net margin of 13.15% and a return on equity of 77.58%. The company’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.43 earnings per share. On average, equities analysts anticipate that Zoetis will post $1.91 EPS for the current fiscal year.
In other news, insider Heidi C. Chen sold 32,097 shares of the stock in a transaction that occurred on Thursday, September 1st. The shares were sold at an average price of $50.98, for a total transaction of $1,636,305.06. Following the sale, the insider now owns 46,060 shares in the company, valued at $2,348,138.80. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Michael B. Mccallister purchased 2,000 shares of the business’s stock in a transaction dated Tuesday, September 6th. The shares were purchased at an average price of $51.34 per share, for a total transaction of $102,680.00. The disclosure for this purchase can be found here. Insiders own 0.05% of the company’s stock.
Large investors have recently bought and sold shares of the stock. AHL Partners LLP bought a new stake in shares of Zoetis during the second quarter valued at about $214,000. Meiji Yasuda Asset Management Co Ltd. bought a new stake in shares of Zoetis during the second quarter valued at about $259,000. Jefferies Group LLC bought a new stake in shares of Zoetis during the second quarter valued at about $289,000. Wetherby Asset Management Inc. boosted its stake in shares of Zoetis by 15.6% in the second quarter. Wetherby Asset Management Inc. now owns 6,339 shares of the company’s stock valued at $301,000 after buying an additional 854 shares in the last quarter. Finally, Usca Ria LLC boosted its stake in shares of Zoetis by 2.9% in the second quarter. Usca Ria LLC now owns 6,700 shares of the company’s stock valued at $318,000 after buying an additional 191 shares in the last quarter. Hedge funds and other institutional investors own 93.12% of the company’s stock.
Several equities analysts have recently commented on ZTS shares. Jefferies Group reaffirmed a “buy” rating and set a $58.00 price objective (up from $57.00) on shares of Zoetis in a research note on Tuesday, June 14th. Zacks Investment Research raised shares of Zoetis from a “hold” rating to a “buy” rating and set a $53.00 price target for the company in a research note on Wednesday, June 15th. Guggenheim reissued a “buy” rating and issued a $60.00 price target on shares of Zoetis in a research note on Monday, July 18th. Barclays PLC increased their price target on shares of Zoetis from $45.00 to $49.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 4th. Finally, Citigroup Inc. increased their price target on shares of Zoetis from $50.00 to $53.00 and gave the stock a “neutral” rating in a research note on Thursday, August 4th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $55.27.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.